Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
11 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
XEOS MEDICAL from Gent, company number BE0738435957, closed financial year 2025 with a result of € -4.3 million after tax. For that financial year XEOS MEDICAL recorded a gross margin of € -1.5 million and equity of € 4 million. Compared with financial year 2024, the result moved from € -3.7 million to € -4.3 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 27, 2026.
€ 4 million
▲ € 3.4 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -4.3 million
▼ 18 % more loss than in 2024
Profit after tax over the fiscal year.
€ 3.3 million
▲ € 2.9 million vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3 million.
People and assets in 2025
23.9
▲ 1.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.3 million
▲ 4% vs 2024
€ 97,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 264,822
▼ 9% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 966,278
▼ 44% vs 2024
€ 58,703 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 223,517
▲ 111% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 256,241
▼ 16% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -1,203,657 | € -1,388,652 | € -1,216,509 | € -1,512,837 | ▼ € 296,328 |
| Profit after taxes | € -2,685,727 | € -3,394,770 | € -3,683,427 | € -4,332,591 | ▼ € 649,165 |
| Equity | € 2,989,530 | € 2,174,761 | € 620,934 | € 4,020,610 | ▲ € 3.4 million |
| Total debts | € 396,678 | € 489,629 | € 2,156,223 | € 1,474,293 | ▼ 32% |
| Cash | € 2,254,422 | € 874,053 | € 411,980 | € 3,305,617 | ▲ € 2.9 million |
| Retained profit | € -5,377,870 | € -4,772,639 | € -3,734,066 | € -3,036,657 | ▲ € 697,409 |
| Bank debt | € 73,556 | € 39,499 | € 1,722,655 | € 966,278 | ▼ 44% |
| Balance sheet total | € 3,386,209 | € 2,664,390 | € 2,777,157 | € 5,494,903 | ▲ 98% |
| Employees (FTE) | 13.2 | 17.5 | 22.8 | 23.9 | ▲ 1.1 |
Key figures of XEOS MEDICAL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to XEOS MEDICAL?
What happened at XEOS MEDICAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Patrick Keereman stepped down as director. NBB
- Guido Van der Schueren stepped down as director. NBB
- Walter Mastelinck stepped down as director. NBB
- Dr. Vincent Keereman, Neurologie BV stepped down as director. NBB
- Lloyd Diamond stepped down as director. NBB
- X-square BV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 4.3 million. Source: NBB ↗
- X-square BV became a director. NBB
In short
From € 2.7 million loss in 2022 to € 4.3 million loss in 2025.
Paid € 9,262 in corporate taxes since 2022.
A new publication or filing at XEOS MEDICAL? We notify you, reason included.
Follow XEOS MEDICALDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of POWERGRAPH comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
XEOS MEDICALThe shares are held by POWERGRAPH (15.6%). It owns 100% of Xeos Medical Inc itself.
Directors
According to the 2025 annual accounts
Patrick Keereman
Director
Also active at: DRI Groep, INCOMEC, Keletech, VD INDUSTRIES, INCOMEC HOLDING, PEPALOT, AnimAb, Pegasus Holding +1 more
since 2019 · until 2031
Guido Van der Schueren
Director
Also active at: eXplio, KEYWARE SMART CARD DIVISION, POWERGRAPH, EasyOrder, PAYMENT SOLUTIONS, Hybrid Software, HYBRID Software Development
since 2019 · until 2031
Walter Mastelinck
Director
Also active at: CREAPLAN, WATT FACTORY, Feelds, CLOUDS OF CARE, Sigma Invest, VINDEVOGEL FLANDERS, BETOTRACE, MACADAM EUROPE NV +1 more
since 2019 · until 2031
Dr. Vincent Keereman, Neurologie BV
Director · represented by Vincent Keereman
Also active at: CLOUDS OF CARE
since 2024 · until 2031
Lloyd Diamond
Director
since 2024 · until 2031
since 2025 · until 2031
Shareholders
15.6%
Participations
Xeos Medical Inc
100%
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1084 box 301
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
All companies at this address →CANTILLANA
€ 33.8 million revenue · 2025
NUTRIPHYT
€ 2.4 million gross margin · 2025
Cantillana Group
Erudite.Health
€ -485,799 gross margin · 2025
Fire Engineered Solutions
€ 2.7 million gross margin · 2025
+6 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0738.435.957
- VAT number
- BE 0738.435.957
- Registered office
- Kortrijksesteenweg 1084 bus 301, 9051 Gent
- Names & denominations
- XEOS MEDICAL
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 26 November 2019
- Peppol
- Active · Active since 29 Jul 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Overige vormen van onderwijs